Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLEDHR)

• Drug Name: AL-43 Drug Info
• Synonyms: AL-438; CHEMBL266282; A-240610.0; SCHEMBL4172433; BDBM50107347; A-224817.0; 5-Allyl-2,2,4-trimethyl-10-methoxy-2,5-dihydro-1H-1-aza-6-oxachrysene; 5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; 5-allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinoline; (+/-)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene; (+)5-Allyl-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9906282
  TTD Drug ID: DMLEDHR

Molecule-Related Drug Atlas

Drug(s) Targeting Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[3]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[4]
Ulipristal	DMBNI20	Contraception	QA21	Approved	[5]
Etonogestrel	DMKA8J4	Contraception	QA21	Approved	[6]
Megestrol	DMDH9KX	Breast cancer	2C60-2C65	Approved	[7]
Segesterone acetate; ethinyl estradiol	DMFEGB0	Contraception	QA21	Approved	[8]
Norgestimate	DMYP4XC	Acne vulgaris	ED80	Approved	[6]
Dydrogesterone	DMAKIDV	Menstrual disorder	GA20.3	Approved	[9]
Medroxyprogesterone	DMBGWPH	Solid tumour/cancer	2A00-2F9Z	Approved	[9]
Ethynodiol Diacetate	DMZM84R	Contraception	QA21	Approved	[10]

Drug(s) Targeting Glucocorticoid receptor messenger RNA (GCR mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vamorolone	DM047HI	Duchenne muscular dystrophy	8C70.1	Approved	[11]
CORT125281	DMHBOUX	Prostate cancer	2C82.0	Phase 2	[12]
ISIS-GCCR	DMICMNU	Diabetic complication	5A2Y	Phase 2	[13]
ORIC-101	DMR12S0	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
AZD9567	DMAXHC0	Rheumatoid arthritis	FA20	Phase 1	[11]
A-348441	DM25CBW	Type-2 diabetes	5A11	Phase 1	[14]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[15]
(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE	DMTPQ84	Discovery agent	N.A.	Investigative	[16]
deoxycorticosterone	DMW6YLS	Discovery agent	N.A.	Investigative	[16]
LGD-5552	DM67KWM	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting Androgen receptor messenger RNA (AR mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[18]
BAY 86-5044	DMRZLU4	Breast cancer	2C60-2C65	Phase 2	[19]
TRC-253	DMXI8CD	Prostate cancer	2C82.0	Phase 1/2	[12]
IONIS-AR-2.5Rx	DMF2DMS	Prostate cancer	2C82.0	Phase 1/2	[20]
ISIS-AR	DM8P3N5	Prostate cancer	2C82.0	Phase 1	[21]
EZN-4176	DMNPS59	Prostate cancer	2C82.0	Phase 1	[22]
EUGENOL	DM7US1H	Discovery agent	N.A.	Patented	[23]
RU-58841	DMMEAZ2	Acne vulgaris	ED80	Discontinued in Phase 1	[24]
flavone	DMEQH6J	Discovery agent	N.A.	Investigative	[25]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[25]

Drug(s) Targeting Mineralocorticoid receptor (MR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[26]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[27]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[28]
Desoxycorticosterone Acetate	DMS0AFE	Discovery agent	N.A.	Approved	[27]
Desoxycorticosterone Pivalate	DMSA4B3	Addison disease	5A74.0	Approved	[29]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[30]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[27]
Finerenone	DMM4FJ3	Chronic kidney disease	GB61	Approved	[31]
ZK-91587	DMJ94L0	Cardiovascular disease	BA00-BE2Z	Phase 2	[32]
Nerenone	DMBJ3GL	Diabetic nephropathy	GB61.Z	Phase 2	[33]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor messenger RNA (AR mRNA)	TTKPW01	ANDR_HUMAN	Inhibitor	[1]
Glucocorticoid receptor messenger RNA (GCR mRNA)	TTOZRK6	GCR_HUMAN	Inhibitor	[2]
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Inhibitor	[1]
Progesterone receptor (PGR)	TTUV8G9	PRGR_HUMAN	Inhibitor	[1]

References

• [1] Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30.
• [2] Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1721-7.
• [3] Clinical pipeline report, company report or official report of lipocine.
• [4] Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
• [7] Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
• [8] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [9] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
• [10] Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [14] Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90.
• [15] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [16] Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9.
• [17] Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
• [19] Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
• [20] Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2019 Feb;20(2):163-172.
• [21] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [22] 2011 Pipeline of Santaris Pharma.
• [23] Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4.
• [24] Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4.
• [25] Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10.
• [26] Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
• [27] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [28] Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
• [29] Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
• [30] Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
• [31] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [32] ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).